The Indian Pharmaceuticals industry plays a prominent role in the global pharmaceuticals industry. India ranks 3rd worldwide for production by volume and 14th by value. The nation is the largest provider of generic medicines globally, occupying a 20% share in global supply by volume, and is the leading vaccine manufacturer globally. India also has the highest number of US-FDA compliant Pharma plants outside of USA and is home to more than 3,000 pharma companies with a strong network of over 10,500 manufacturing facilities as well as a highly skilled resource pool.
The pharmaceutical industry in India offers 60,000 generic brands across 60 therapeutic categories. Major segments include generic drugs, OTC Medicines, API/Bulk Drugs, Vaccines, Contract Research & Manufacturing, Biosimilars and Biologics.
* Incentives worth INR 21,940 Crore ($3 Bn) are approved
* Market size expected to reach $65 bn by 2024, and ~$130 bn by 2030
* Expected growth rate of 11-12% (2020-2030)
* Cost of manufacturing ~ 33% lower than western markets
Indian pharma companies enabled by their price competitiveness and good quality, have made global mark, with 60% of the world’s vaccines and 20% of generic medicines coming from India.
100% Foreign Direct Investment (FDI) in the Pharmaceutical sector is allowed under the automatic route for greenfield pharmaceuticals.
100% FDI in the pharmaceutical sector is allowed in brownfield pharmaceuticals; wherein 74% is allowed under the automatic route and thereafter through the government approval route.
For further details, please refer FDI Policy
* 20%Generics medicines exports share (global)
* $24.6 BnExports worth (FY 21-22)
* $1.410 BnFDI (April 2021-March 2022)
Comments